Pain Management Drugs Market Analysis, Growth and Forecast to 2023

Pain Management Drugs Market

The growing geriatric population and increasing demand of innovative and advanced pain relaxing medications around the world are the predominant growth drivers for the global pain management drugs market. Additionally, the increasing number of hospitalization cases; unmet requirements for neuropathic pain management drugs; innovative and advanced applications of pain management therapies; increasing prevalence of various chronic diseases, such as cancer, and neurological problems; and increasing healthcare expenditure are also driving the growth of the global market. The growing numbers of mergers and acquisitions is a key trend observed in the market. Among the various therapeutic indications, the post-operative pain relief segment accounted for the largest share, and the low-back pain segment accounted for the second largest share in the global market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/pain-management-drugs-market

Pain management drugs are mainly used to relieve discomfort associated with injury and surgeries. Moreover, pain management medications are used in the management of pain associated with neurological problems, migraine, cancer, orthopedic problems, low- back pain, rheumatoid arthritis, and fibromyalgia.

North America and Europe are the major markets, due to increasing prevalence of chronic diseases, and growing awareness about various types of chronic pain conditions in these regions. The U.S. followed by Canada, is the largest market for pain management drugs in North America. Whereas, the U.K., Germany and France are some of the major countries holding significant share in the European pain management drugs market.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/pain-management-drugs-market/toc-sample

The Asian market is growing with a significant rate, owing to huge pool of patients, and increasing healthcare spending in the region. In addition, the initiatives taken by various government associations to develop chronic pain rehabilitation centers, and increasing prevalence of various chronic diseases are also supporting the growth of the Asian pain management drugs market. The countries such as India, Japan and China, are the major markets in the region.

Some of the major players operating in the global pain management drugs market include Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Forest Laboratories Inc., Endo International PLC, Johnson & Johnson, Pfizer Inc., Valeant Pharmaceuticals International Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., and Baxter International Inc.

Advertisements

Graft Versus Host Disease Treatment Market Pipeline Analysis, Growth and Forecast to 2023

Graft Versus Host Disease Treatment MarketThe global graft versus host disease (GVHD) treatment market is expected to witness considerable growth due to increasing number of hematopoietic stem cell transplantations (HSCTs), advancement in technologies, and increasing collaboration among the pharmaceutical companies. The regulatory bodies are supporting the graft versus host disease market by providing designations and grants for speeding up the drug development process. Currently, there are more than 15 targets, which are being used for the treatment of GVHD including T lymphocytes, OX40, Bruton’s tyrosine kinase, Toll-like receptors, tumor necrosis factor alpha, neutrophil elastase, and several B and T lymphocytes. Some of the companies use their own technologies for the development of drugs for graft versus host disease such as Bellicum Pharmaceuticals, Inc. and Targazyme, Inc.  Bellicum Pharmaceuticals, Inc. is using CaspaCIDe technology and Targazyme, Inc. is using Fucosylation technology.

Explore Report at: https://www.psmarketresearch.com/market-analysis/gvhd-treatment-market

The pipeline of GVHD is very rich with more than 60 drugs. Top pharmaceutical companies such as Dr. Falk Pharma GmbH and Mallinckrodt plc are expected to launch their products in coming years, as the products are in Phase III stage of development. The therapeutics involved in the treatment of GVHD comprise different molecule types including antibody drug conjugate, antibodies, cell therapy, monoclonal antibodies and recombinant proteins.

Geographically, North America was the largest market for GVHD treatment in 2015, owing to the high incidence of HSCTs, high healthcare expenditure and large number of research and development activities. The U.S. contributed largest revenue to the North American GVHD treatment market and it is expected to remain the largest market globally, during the forecast period.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/gvhd-treatment-market/toc-sample

Some of the key players operating in the global market are Dr. Falk Pharma GmbH, Mallinckrodt Pharmaceuticals, Apceth GmbH & Co. KG, Targazyme Inc., Bellicum Pharmaceuticals, Inc., Cellect Biotechnology Ltd., Sanofi, Novartis AG, Gilead Sciences, Inc., AbbVie Inc., and Takeda Pharmaceutical Company Ltd.

mTOR Inhibitors Market Pipeline Analysis, Growth and Forecast to 2023

mTOR Inhibitors Market

The global mammalian target of rapamycin (mTOR) inhibitors market is witnessing considerable growth due to their application in several therapeutic areas such as cancer, renal dysfunction and eye disorders. The regulatory bodies are providing funding and designation to the drug candidates for advancement of their products. Moreover, the increasing awareness related to the effective use of mTOR inhibitors, in combination with chemotherapy and its implications in cancer therapy is also supporting the growth of global market. Different classification of mTOR inhibitors and their unique features is leading to their increased demand. Among the different generations of mTOR inhibitors, third generation mTOR inhibitors exploit the unique juxtaposition of two drug-binding pockets to create a bivalent interaction that allows inhibition of resistant mutants.

Explore Report at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-market

The involvement of antibiotics and proteins for drug development and technological advancements for mTOR inhibitors are expected to create ample growth opportunities for the global market. However, high cost of the marketed drugs and complexity in understanding the mechanism of action are the limitations associated with mTOR inhibitors, which are hampering the growth of the global market.

Geographically, North America was the largest market for mTOR inhibitors in 2015, owing to the large number of research and development activities, high healthcare expenditure, and high prevalence of chronic diseases such as cancer and cardiovascular diseases. The U.S. contributed largest revenue to the North American mTOR inhibitors market and it is expected to remain the largest market globally, during the forecast period. The supporting government regulations taken by the federal government is the key driving factor of the U.S. mTOR inhibitors market.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-market/toc-sample

The key players operating in the global market are Pfizer Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Ability Pharma, GlaxoSmithKline, MEI Pharma, Verastem, Inc., Phusis Therapeutics, Inc., and Co-D Therapeutics, Inc.

Endometrial Cancer Treatment Market Pipeline Analysis, Share and Forecast to 2023

Endometrial Cancer Treatment Market

The global endometrial cancer treatment market is expected to witness growth due to unmet need of treatment, technological advancement in cancer therapeutics and diagnostic test, rising prevalence of cancer, and sedentary lifestyle of women. In addition, increasing awareness about the uterine diseases and the available therapies and increasing healthcare expenditure is also driving the growth of global endometrial cancer treatment market.

Explore Full Report at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market

The pharmaceutical companies are actively involved in the endometrial cancer research and development. AEterna Zentaris, Inc., is developing Zoptrex (zoptarelin doxorubicin), a Phase III clinical trial drug candidate for the treatment of endometrial cancer. In October 2016, the company entered into licensing agreement with Specialized Therapeutics Asia, a biopharmaceutical company, for the marketing of zoptarelin doxorubicin in Australia and New Zealand.

Endometrial cancer is an abnormal growth of uterus, in which inner lining of the uterus known as endometrium got affected. The American Cancer Society estimated that in year 2016, about 60,050 new cases of endometrial cancer would be diagnosed in the U.S. and about 10,470 women would die from cancers of the uterine body. The sign and symptoms of endometrial cancer is abnormal vaginal bleeding. It is most often diagnosed by pelvic ultrasound and transvaginal ultrasound. An endometrial biopsy is also preferred in postmenopausal women with endometrial cancer.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market/toc-sample

Some of the key players operating in the global market are Bristol-Myers Squibb Company, Merck & Co., Inc., Ariad Pharmaceuticals Inc., GlaxoSmithKline plc, Novartis AG, Sanofi, Eisai Co., Ltd., Exelixis, Inc., F. Hoffmann-La Roche AG, and Abbott Laboratories.

Immune Checkpoint Inhibitors Market Analysis, Size & Forecast to 2023

Immune Checkpoint Inhibitors Market

The global immune checkpoint inhibitors market is expected to witness significant growth as these are proven to be more effective therapy in shrinking tumor in higher proportion of patients, as compared to other immunotherapies. Immune checkpoint inhibitors are applicable to a wider range of tumor types such as advanced or metastatic non-small cell lung cancer, renal cancer and melanoma. These inhibitors lower the rate of severe toxicities and immune-mediated side-effects. These are also convenient to administer and yield a good response rate of any single-agent immunotherapy.

Explore Report at: https://www.psmarketresearch.com/market-analysis/immune-checkpoint-inhibitors-market

The pharmaceutical companies are actively involved in the research and development of drug for immune checkpoint inhibitors. The pipeline of immune checkpoint inhibitors is rich with more than 50 drugs. In November 2016, Bristol-Myers Squibb Company and Infinity Pharmaceuticals collaborated to check the efficacy of combination of Opdivo (a PD-1 inhibitor monoclonal antibody) and IPI-549 (a phosphoinositide-3-kinase gamma inhibitor) in patients with advanced solid tumors.

Immune checkpoint inhibitors are showing good efficacy with PD-1 and PD-L1 inhibitors and CTLA-4 inhibitors. Yervoy, an anti-CTLA-4 product of Bristol-Myers Squibb Company got approved in the year 2011. The increased use of combination therapy of PD-1 and PD-L1 inhibitors represent a new signal of immunotherapeutics, which is expected to alter the standard of care for cancer across the globe. However, the development of effective immunotherapy presents some challenges due to complex pathophysiology of cancer and difficulty in managing treatment related toxic effects, which is expected to hamper the growth of the global market to some extent.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/immune-checkpoint-inhibitors-market/toc-sample

Some of the key players operating in the global market are Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Regeneron Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and TG Therapeutics, Inc.

Nonalcoholic Steatohepatitis Therapeutics Market – Analysis, Size, Growth and Forecast to 2023

Nonalcoholic Steatohepatitis (NASH) Therapeutics Market

The global nonalcoholic steatohepatitis therapeutics market is expected to witness significant growth due to current unmet medical need of NASH, scarcity of the permanent treatment of the disease, increasing prevalence of obesity, and high demand for safe and effective medication. The regulatory bodies are supporting the NASH market by providing designations and funding for speeding up the drug development process. In March 2015, obeticholic acid, an investigational Phase III clinical trial drug candidate of Intercept Pharmaceuticals Inc., received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of patients with NASH.

Explore Report at: https://www.psmarketresearch.com/market-analysis/nash-therapeutics-market

The pipeline of NASH therapeutics is rich with more than 50 drugs. The pharmaceutical companies are actively involved in the research and development of drug for NASH. In June 2016, The Zydus Cadila initiated Phase III clinical trials of Saroglitazar to study its effect in adult NASH patients.

A large number of pharmaceutical companies are investing huge capital for the development of NASH therapeutics. However, certain factors such as unknown etiology, complex pathophysiology, and high treatment cost of NASH are expected to hamper the growth of the global market during the forecast period.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/nash-therapeutics-market/toc-sample

Geographically, North America is expected to be the largest market for NASH therapeutics owing to the large number of research and development activities, high healthcare expenditure and high incidence of obesity. The U.S. contributed largest revenue to the North American market and it is expected to remain the largest market globally, during the forecast period.

Some of the key players operating in the global NASH therapeutics market are Genfit SA, Gilead Sciences, Inc., Novo Nordisk A/S, Intercept Pharmaceuticals, Inc., Enzo Biochem, Inc., Raptor Pharmaceutical Corp., Conatus Pharmaceuticals Inc., Zydus Cadila Healthcare Limited., Novartis AG, and Shire plc.

Blood Collection Market – Trends, Analysis and Research Report, 2023

Blood Collection Market

The global blood collection market is witnessing considerable growth due to increasing geriatric population, increasing number of accidental cases and growing surgical procedures. Moreover, growing prevalence of chronic diseases including cancer, cardiovascular disease, infectious diseases, autoimmune diseases, diabetes mellitus, and infectious diseases is supporting the growth of the market. Based on product type, the blood collection needle and syringe segment lead the market. The increasing demand of needle and syringe for blood collection across the globe, owing to their easy availability and ease of use, is driving the growth of this segment. In addition, rising initiatives undertaken by government associations to boost awareness about blood donations and advanced features of blood collection products are also supporting to the growth of this market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/blood-collection-market

The use of RFID technology in blood banks and transfusion medicine has the potential to improve operational efficiency. It helps in providing patient safety at point of care by automatically identifying, reconciling, and tracking blood products throughout the blood supply chain. The increasing use of radiofrequency identification (RFID) and needle free devices is expected to create opportunities for the manufacturers of blood collection products. However, risk associated with blood transfusions and growing needlestick injuries are the key factors hampering the growth of the global market.

Geographically, North America has been the largest market for blood collection, owing to increased awareness, established healthcare industry, and easy increasing prevalence of infectious and non-infectious diseases in the region. The U.S. contributed largest revenue to the North American as well as global blood collection market. The presence of large number of diagnostic laboratories and hospitals, and increasing prevalence of people with blood disorders are the key growth driving factors for the U.S. blood collection market.

Request For Table of Content at: https://www.psmarketresearch.com/market-analysis/blood-collection-market/toc-sample

The key players operating in the global blood collection market are Abbott Laboratories Inc., Becton, Dickinson and Company, Terumo Corporation, Sarstedt AG & Co., Nipro Medical Corporation, Qiagen, Haemonetics Corporation, Greiner Holding AG and F.L. Medical SRL.

Cartilage Repair Market Size, Share and Forecast to 2023

Cartilage Repair MarketThe global cartilage repair market is witnessing considerable growth due to increasing geriatric population, increasing obesity, increasing healthcare expenditure, and growing sports related injuries. Moreover, increase in innovative product launches and growth of medical tourism leading to awareness about the cartilage treatment modalities across the globe is supporting the growth of the market. Based on the treatment modalities, cell-based approaches segment is expected to grow at the fastest rate during the forecast period, due to long term results of this treatment.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cartilage-repair-market

Obesity is a serious health concern in the U.S. The increasing prevalence of obesity is driving the growth of the cartilage repair market in the U.S. According to CDC, during 2011-2012, 35.1% of adult aged 20 years or above were obese. In addition, as published by the Organization for Economic Cooperation and Development (OECD) in the year 2014, the obesity rate in Germany increased from 11.5% in 1999 to 14.7% in 2009. This increase in obesity rate leads to increase in demand for liposuction procedures, which is further accelerating the market growth.

Europe has been the second largest market for cartilage repair, where the market is driven by the increasing demand for cell-based approaches, increasing healthcare expenditure and launch of novel products. In 2015, Germany led the European cartilage repair market and it is also expected to grow at the fastest rate in Europe, during the forecast period. Globally, the cartilage repair market is expected to witness the fastest growth in Asia-Pacific during the forecast period, attributed to the increasing per capita income leading to improved standard of living, increasing healthcare spending, growing demand for better quality medical care, and awareness about cartilage repair treatments in the region.

Request For Table of Content at: https://www.psmarketresearch.com/market-analysis/cartilage-repair-market/toc-sample

The key players operating in the global cartilage repair market are Zimmer Biomet Holdings, Inc., Johnson & Johnson, Vericel Corporation, Smith & Nephew PLC, Osiris Therapeutics, Inc., RTI Surgical, Conmed Linvatec, B. Braun Melsungen AG, Anika Therapeutics S. R. L.  and Arthrex, Inc.

Cold Pain Therapy Market – Global Industry Insight, Size and Forecast to 2023

Cold Pain Therapy Market

The popularity of cold pain therapy products is due to presence of several pain relief products in market. These products include creams, gels, ointments, sprays, cold packs, rolls, cooling towels, motorized and non-motorized devices. Based on application, the musculoskeletal disorders segment lead the global market due to increasing cases of arthritis, osteoarthritis, joint pain and back pain across the globe.

Explore report at: https://www.psmarketresearch.com/market-analysis/cold-pain-therapy-market

The rapid growth in emerging economies and technological advancement in development of more effective products is expected to create further growth opportunities for the manufacturers of cold pain therapy products. However, high cost of prescription based products, lack of reimbursement and health hazards associated with the usage of cold therapy products are the key factors hampering the growth of the global market.

Geographically, North America has been the largest market for cold pain therapy, owing to increased awareness, and easy accessibility to advanced technologies including motorized and non-motorized devices. Moreover, increasing incidence of musculoskeletal conditions drives the market growth in the region. The U.S. contributed largest revenue to the North American as well as global cold pain therapy market. The presence of large pool of patients with back pain, muscular pain and arthritis is the key driving factor of the U.S. cold pain therapy market.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/cold-pain-therapy-market/toc-sample

The key players operating in the global cold pain therapy market are Johnson & Johnson, Sanofi, 3M Company, Hisamitsu Pharmaceutical Co., Inc., Rohto Pharmaceutical Co., Ltd., Medline Industries, Inc., Beiersdorf AG, Breg, Inc., Össur HF and DJO Finance LLC.

Topical Drug Delivery Market Trends, Size, Demand and Forecast to 2023

Drugs that are applied to a local area on the body are known as topical drugs. Many creams and balms that are used for skin treatment are frequently called topical drug. Topical drug delivery market offers an alternative drug delivery system to treat many diseases and related conditions such as psoriasis, ringworm, rashes & blisters and others. The topical drug delivery has turned out to be progressively essential in the pharmaceutical industry. Eye drops and drugs utilized for inward breath in respiratory conditions such as asthma are also frequently known as topical medications. Topical medications have a local effect that means the effect of the drug will be only in the area where the drug has been applied; however, some topical medications can also have a systemic effect.

Explore Report at: https://www.psmarketresearch.com/market-analysis/topical-drug-delivery-market

The global topical drug delivery market is segmented on the basis of the product type, route of administration, indication for which the drug is used and its end users. Based on product type the market is segmented into formulations and devices, formulations are further sub-segmented into solid, liquid and semi-solid formulations, and devices. Semi-solid formulations include ointment, cream, gel lotion and paste and had a major contribution in the global topical drug delivery market in 2016, as compared to other sub-segments. The major factors driving the growth of semi-solid formulations include increasing rate of blood donations and rise in the number of surgical procedures such as organ transplantation where these formulations are widely used.

There are various factors that drive the growth of the topical drug delivery market including the increasing prevalence of dermal diseases, development of high technology in topical drug delivery systems, high number of cases of burn injuries, and increasing prevalence of diabetes, globally. According to the World Health Organization (WHO), the prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014, globally. Also, the WHO estimates that, diabetes would be the seventh leading cause of death, by 2030.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/topical-drug-delivery-market/report-sample

In December 2016, Sienna Biopharmaceuticals, Inc., announced that it had acquired Creabilis plc, a company focused on developing topical treatments for inflammatory diseases including atopic dermatitis, psoriasis and pruritus. The acquisition was done to acquire patented and first-in-class late-stage clinical candidates, including topical TrkA/janus kinase 3 (JAK3) inhibitor (SNA-125, formerly CT340) and Phase IIb topical tropomyosin receptor kinase A (TrkA) inhibitor (SNA-120, formerly CT327) for the treatment of skin conditions such as psoriasis and pruritus.

Some of the other key players operating in the global topical drug delivery market include Crescita Therapeutics Inc., SOLVAY S.A., Bayer AG, Cipla Limited, Galderma S.A, GlaxoSmithKline PLC, Janssen Global Services, LLC. (Johnson and Johnson), Novartis International AG, Sienna Biopharmaceuticals, Inc., Allergan PLC.